The purpose of this study is to compare the effectiveness of two medications – duloxetine versus pregabalin – for cancer patients with nerve pain that is unresponsive to opioid medications. Patients will take either duloxetine or pregabalin for three weeks as the dose is gradually increased. Allocation to either medication is random and researchers and patients will be unaware of which medication is being taken.
This trial is accepting participants until March 2025.
Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.
Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...
Working as a research assistant in an immunology research lab, Yvonne Gautam learnt what a clinical trial was after being asked to set up a lab for a Phase Two clinical trial.